Characterization of Duvelisib in Patients With Refractory Marginal Zone Lymphoma: Data From the Phase 2 Dynamo Trial

Hematological Oncology - United Kingdom
doi 10.1002/hon.70_2631
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Copanlisib Treatment of Patients With Relapsed or Refractory Marginal Zone Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Umbralisib Monotherapy Demonstrates Efficacy and Safety in Patients With Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter, Open-Label, Registration Directed Phase 2 Study

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Phase 2 Trial of Rituximab and Bortezomib in Patients With Relapsed or Refractory Mantle Cell and Follicular Lymphoma

Cancer
Cancer ResearchOncology
2010English

Elara: A Phase 2 Trial Investigating the Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory/Relapsed Follicular Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Obinutuzumab Therapy in Patients With Marginal Zone and Mantle Cell Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Splenic Marginal Zone Lymphoma

2020English

Phase Iiib Study of Lenalidomide Plus Rituximab Followed by Maintenance in Relapsed or Refractory Nhl: Analysis of Marginal Zone Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Effect of Dose Modifications on Response to Duvelisib in Patients With Relapsed/Refractory CLL/SLL in the Duo Trial

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Marginal Zone B-Cell Lymphoma

English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy